The Use of Ionization Electron Columns for Space-Charge Compensation in High Intensity Proton Accelerators

We discuss a recent proposal to use strongly magnetized electron columns created by beam ionization of the residual gas for compensation of space charge forces of high intensity proton beams in synchrotrons and linacs. The electron columns formed by trapped ionization electrons in a longitudinal magnetic field that assures transverse distribution of electron space charge in the column is the same as in the proton beam. Electrostatic electrodes are used to control the accumulation and release of the electrons. Ions are not magnetized and drift away without affecting the compensation. Possible technical solution for the electron columns is presented. We also discuss the first numerical simulation results for space-charge compensation in the FNAL Booster and results of relevant beam studies in the Tevatron

Risk Analysis on BOT Investment Project

随着城市化水平的不断提高和市场化程度的深入，我国的水务市场表现出旺盛的投资需求。政府在引进资金的同时，不断改善投资环境，吸引了包括国际、民营以及其他投资者的积极参与。而BOT投资方式以其“带来资金、引进先进技术和设备、提高管理水平”的特点，逐渐为各地政府和广大投资者所青睐。然而，由于我国水务业的改革尚处于起步阶段，政府和投资者对BOT的认识还未到位，在水务BOT投资中面临着各种各样的风险。重视投资风险的研究，是投资项目得以顺利实施的前提。关于投资风险分析的研究较多，但很少有对水务业BOT投资项目进行动态模拟分析的。本文采用蒙特卡罗法，对影响水务BOT投资项目的可计量风险因素进行模拟分析，动态描...With the increasing improvement of the urbanization and the development of marketization, investment is in deep demand in Chinese urban water supply and wastewater treatment market. While trying to introduce capital, the government steadily better investment environment and attract the participants from foreign capitals, civilian capitals and other investors. However, Build-Operate-Transfer (BOT) ...学位：工商管理硕士院系专业：管理学院工商管理教育中心_工商管理硕士(MBA)学号：20031504

Coupled optics reconstruction from TBT data using MAD-X

Turn-by-turn BPM data provide immediate information on the coupled optics functions at BPM locations. In the case of small deviations from the known (design) uncoupled optics some cognizance of the sources of perturbation, BPM calibration errors and tilts can also be inferred without detailed lattice modeling. In practical situations, however, fitting the lattice model with the help of some optics code would lead to more reliable results. We present an algorithm for coupled optics reconstruction from TBT data on the basis of MAD-X and give examples of its application for the Fermilab Tevatron accelerator

Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial

Aims  The third Universal Definition of Myocardial Infarction (MI) Task Force classified MIs into five types: Type 1, spontaneous; Type 2, related to oxygen supply/demand imbalance; Type 3, fatal without ascertainment of cardiac biomarkers; Type 4, related to percutaneous coronary intervention; and Type 5, related to coronary artery bypass surgery. Low-density lipoprotein cholesterol (LDL-C) reduction with statins and proprotein convertase subtilisin–kexin Type 9 (PCSK9) inhibitors reduces risk of MI, but less is known about effects on types of MI. ODYSSEY OUTCOMES compared the PCSK9 inhibitor alirocumab with placebo in 18 924 patients with recent acute coronary syndrome (ACS) and elevated LDL-C (≥1.8 mmol/L) despite intensive statin therapy. In a pre-specified analysis, we assessed the effects of alirocumab on types of MI. Methods and results  Median follow-up was 2.8 years. Myocardial infarction types were prospectively adjudicated and classified. Of 1860 total MIs, 1223 (65.8%) were adjudicated as Type 1, 386 (20.8%) as Type 2, and 244 (13.1%) as Type 4. Few events were Type 3 (n = 2) or Type 5 (n = 5). Alirocumab reduced first MIs [hazard ratio (HR) 0.85, 95% confidence interval (CI) 0.77–0.95; P = 0.003], with reductions in both Type 1 (HR 0.87, 95% CI 0.77–0.99; P = 0.032) and Type 2 (0.77, 0.61–0.97; P = 0.025), but not Type 4 MI. Conclusion  After ACS, alirocumab added to intensive statin therapy favourably impacted on Type 1 and 2 MIs. The data indicate for the first time that a lipid-lowering therapy can attenuate the risk of Type 2 MI. Low-density lipoprotein cholesterol reduction below levels achievable with statins is an effective preventive strategy for both MI types.For complete list of authors see http://dx.doi.org/10.1093/eurheartj/ehz299</p

Effect of alirocumab on mortality after acute coronary syndromes. An analysis of the ODYSSEY OUTCOMES randomized clinical trial

Background: Previous trials of PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitors demonstrated reductions in major adverse cardiovascular events, but not death. We assessed the effects of alirocumab on death after index acute coronary syndrome. Methods: ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) was a double-blind, randomized comparison of alirocumab or placebo in 18 924 patients who had an ACS 1 to 12 months previously and elevated atherogenic lipoproteins despite intensive statin therapy. Alirocumab dose was blindly titrated to target achieved low-density lipoprotein cholesterol (LDL-C) between 25 and 50 mg/dL. We examined the effects of treatment on all-cause death and its components, cardiovascular and noncardiovascular death, with log-rank testing. Joint semiparametric models tested associations between nonfatal cardiovascular events and cardiovascular or noncardiovascular death. Results: Median follow-up was 2.8 years. Death occurred in 334 (3.5%) and 392 (4.1%) patients, respectively, in the alirocumab and placebo groups (hazard ratio [HR], 0.85; 95% CI, 0.73 to 0.98; P=0.03, nominal P value). This resulted from nonsignificantly fewer cardiovascular (240 [2.5%] vs 271 [2.9%]; HR, 0.88; 95% CI, 0.74 to 1.05; P=0.15) and noncardiovascular (94 [1.0%] vs 121 [1.3%]; HR, 0.77; 95% CI, 0.59 to 1.01; P=0.06) deaths with alirocumab. In a prespecified analysis of 8242 patients eligible for ≥3 years follow-up, alirocumab reduced death (HR, 0.78; 95% CI, 0.65 to 0.94; P=0.01). Patients with nonfatal cardiovascular events were at increased risk for cardiovascular and noncardiovascular deaths (P<0.0001 for the associations). Alirocumab reduced total nonfatal cardiovascular events (P<0.001) and thereby may have attenuated the number of cardiovascular and noncardiovascular deaths. A post hoc analysis found that, compared to patients with lower LDL-C, patients with baseline LDL-C ≥100 mg/dL (2.59 mmol/L) had a greater absolute risk of death and a larger mortality benefit from alirocumab (HR, 0.71; 95% CI, 0.56 to 0.90; Pinteraction=0.007). In the alirocumab group, all-cause death declined wit h achieved LDL-C at 4 months of treatment, to a level of approximately 30 mg/dL (adjusted P=0.017 for linear trend). Conclusions: Alirocumab added to intensive statin therapy has the potential to reduce death after acute coronary syndrome, particularly if treatment is maintained for ≥3 years, if baseline LDL-C is ≥100 mg/dL, or if achieved LDL-C is low. Clinical Trial Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01663402

MADX-SC Flag Description

MADX-SC allows to treat frozen space charge using beam-beam elements in a thin lattice. Here the necessary flags will be discussed